On the other hand, type II EOC cells Pirfenidone molecular weight are able to create a tolerant microenvironment and prevent an immune response by inducing macrophages’ to secrete IL-10 and by promoting the generation of T regs. Conclusion We demonstrate that each ovarian cancer cell subpopulation can induce a unique phenotype of macrophages and T cells, both associated with tumor-supportive function. “
“While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML), the disease has a high probability of relapse. Strategies to prevent relapse involve consolidation chemotherapy, stem cell transplantation and immunotherapy. Evidence for
immunosurveillance
of AML and susceptibility of leukaemia cells to both T cell and natural killer (NK) cell attack and justifies the application of immune strategies to control residual AML persisting after remission induction. Immune therapy for AML includes allogeneic stem cell transplantation, adoptive transfer of allogeneic or autologous T cells or NK cells, vaccination with leukaemia cells, dendritic cells, cell lysates, peptides and DNA vaccines and treatment with cytokines, antibodies and immunomodulatory agents. Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a Nitroxoline view to achieving Wnt inhibitor leukaemia cure. In the 1970s it became apparent that the recently introduced chemotherapeutic agents daunorubicin and cytosine arabinoside could achieve remissions in a substantial number of patients with acute myeloid leukaemia (AML). However, unlike the experience with childhood
acute lymphoblastic leukaemia, it was clear that remissions were not usually maintained by consolidation and maintenance treatments [1]. This was the incentive to explore the idea of preventing relapse by vaccinating patients against leukaemia at remission, when the disease was at a low residual level. One vaccine trial with bacille Calmette–Guérin (BCG) and irradiated autologous leukaemia cells did report prolonged remission and survival in the vaccinated group [2], but interest in vaccination waned with the development of high-dose therapy and stem cell transplantation (SCT) to sustain remissions. An important lesson from allogeneic SCT was that the donor immune system could confer a graft-versus-leukaemia (GVL) effect whose potency has been realized increasingly over the last few decades, supporting a role for both donor T cells and natural killer (NK) cells in the suppression and elimination of residual leukaemia after SCT [3].